Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Irritation Potential of PBI-100
NCT04882631Phase 1Completed
- Sponsor
- Pyramid Biosciences
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of PBI-100 in psoriasis and atopic dermatitis (AD), sponsored by Pyramid Biosciences. Primary endpoint: Skin Irritation Potential at 21 days. Started Apr 2021; status: completed.
02
Drugs
PBI-100
03
Conditions
psoriasisatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04882631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882631.